← All trials
NCT06517758
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Dec 28, 2026
- Completion date
- Jan 12, 2029
- First posted
- Jul 24, 2024
- Last posted
- Aug 26, 2024
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovartisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.